Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Tonix Pharmaceuticals (Nasdaq: TNXP) said management will participate in two investor conferences in March 2026: a company presentation at TD Cowen on March 4, 2026 and 1x1 meetings at Barclays from March 10–12, 2026.

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) said management will participate in two investor conferences in March 2026: a company presentation at TD Cowen on March 4, 2026 and 1x1 meetings at Barclays from March 10–12, 2026.

A live webcast of the March 4 presentation will be available on the company's Investor Events page, with a replay accessible for 90 days. The company highlighted its recently approved flagship product TONMYA and a CNS and immunology pipeline including TNX-2900, TNX-4800, and TNX-1500.

Argus Feb 25 session

+3.85% close to close Open Argus

Details

News Market Reaction – TNXP

On Feb 25, the day this news came out, TNXP closed 3.85% above the previous close.

Data tracked by StockTitan Argus for the Feb 25 session.

Key Figures

TONMYA dose: 2.8 mg Conference date: March 4, 2026 Presentation time: 11:10–11:40 AM ET +5 more

TONMYA dose

2.8 mg

Cyclobenzaprine HCl sublingual tablets strength for fibromyalgia

Conference date

March 4, 2026

TD Cowen 46th Annual Healthcare Conference presentation date

Presentation time

11:10–11:40 AM ET

Scheduled slot at TD Cowen conference

Barclays meetings window

March 10–12

1x1 investor meetings at Barclays Healthcare Conference

Webcast replay period

90 days

Length of time conference replay will be accessible

Fibromyalgia treatment gap

more than 15 years

TONMYA as first new fibromyalgia treatment in this period

Phase 2 trials

Phase 2

TONMYA studies in major depressive disorder and acute stress disorder

TNX-2900 stage

Phase 2 ready

Development stage for Prader-Willi syndrome program

Historical Context

5 past events · Latest: Jan 30

5 events

1. Jan 30

   Phase 3 data

   24h Move

   -5.4%

   Positive Phase 3 RESILIENT fibromyalgia data for TONMYA presented at summit.

2. Jan 06

   Investor conferences

   24h Move

   +0.9%

   January 2026 investor conference presentations and 1x1 meeting availability.

3. Dec 29

   Direct offering

   24h Move

   +0.1%

   $20.0M registered direct equity offering to fund commercialization and pipeline.

4. Dec 29

   Program update

   24h Move

   +0.1%

   Program updates on TNX-4800 Lyme disease prophylaxis, planning 2026 FDA meeting.

5. Dec 16

   Licensing deal

   24h Move

   -1.4%

   Exclusive license of TNX-4900 Sigma-1 antagonist for chronic neuropathic pain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

sublingual, central nervous system, monoclonal antibody, fibromyalgia, +4 more

8 terms

sublingual medical

"TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg)"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

central nervous system medical

"commercial-stage biotechnology company focused on central nervous system (CNS) and immunology"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

monoclonal antibody medical

"monoclonal antibody TNX-4800 for Lyme disease prophylaxis"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

fibromyalgia medical

"first new treatment for fibromyalgia in more than 15 years"

Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.

major depressive disorder medical

"evaluate its potential in major depressive disorder and acute stress disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

Prader-Willi syndrome medical

"TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

CD40 ligand inhibitor medical

"TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection"

A CD40 ligand inhibitor is a drug that blocks the CD40 ligand, a protein used by immune cells to send activation and inflammatory signals; think of it as turning down an alarm bell that rallies the immune system. Investors care because these drugs aim to treat autoimmune diseases, transplant rejection or inflammatory conditions, so their clinical trial results, safety profile and regulatory approval prospects directly affect a company’s future revenue potential and development risk.

webcast technical

"A live webcast of the presentation will be available on the Events page"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026:

TD Cowen 46^th Annual Healthcare Conference
Company Presentation
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Wednesday March 4, 2026
Place: Boston Marriott Copley Place
Time: 11:10 AM – 11:40 AM ET
Room: MIT, 3^rd Floor

Barclays 28^th Annual Healthcare Conference
Company Participation
Management will be available for 1x1 meetings, March 10 - 12, at the Loews Miami South Beach Hotel

If you are interested in meeting with Tonix Pharmaceuticals at any of these conferences, please reach out to your respective TD Cowen and Barclays representatives. A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events. A replay of the webcast will be accessible for 90 days following the event.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contacts
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Tonix (TNXP) present at the TD Cowen 46th Annual Healthcare Conference?

Tonix (TNXP) will present at TD Cowen on March 4, 2026, 11:10–11:40 AM ET in Boston. According to the company, Seth Lederman, M.D., CEO, will deliver the presentation and a live webcast will be available on the company's investor events page.

How can investors schedule meetings with Tonix (TNXP) at the Barclays 28th Annual Healthcare Conference on March 10–12, 2026?

Management will be available for 1x1 meetings March 10–12, 2026, at Loews Miami South Beach Hotel. According to the company, interested investors should contact their TD Cowen or Barclays representatives to arrange meetings.

Where will the Tonix (TNXP) March 4, 2026 presentation webcast be hosted and how long is the replay available?

The live webcast will be hosted on the company's Investor Events page and replay will be available for 90 days. According to the company, investors can access the webcast and replay via the Events page on its investor website.

What topics will Tonix (TNXP) management cover during the March 2026 investor presentations?

The presentations will cover commercial progress, the recently approved TONMYA product, and the company's CNS and immunology pipeline. According to the company, management will discuss TONMYA, TNX-2900, TNX-4800, TNX-1500, and related clinical programs.

What is TONMYA and why is it notable for Tonix (TNXP) investors?

TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is Tonix's recently approved flagship fibromyalgia medicine. According to the company, it is the first new fibromyalgia treatment in more than 15 years and is being evaluated in Phase 2 trials for additional CNS indications.